These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16986273)

  • 1. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).
    Varner JD
    Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD; Sharma SK; Begent RH
    Expert Opin Biol Ther; 2004 Nov; 4(11):1777-89. PubMed ID: 15500406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1421-31. PubMed ID: 17069527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.
    Syrigos KN; Epenetos AA
    Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
    Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
    Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data.
    Baxter LT; Jain RK
    Br J Cancer; 1996 Feb; 73(4):447-56. PubMed ID: 8595158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
    Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in antibody-directed enzyme prodrug therapy.
    Sharma SK; Bagshawe KD; Begent RH
    Curr Opin Investig Drugs; 2005 Jun; 6(6):611-5. PubMed ID: 15997480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-glucuronidase-mediated drug release.
    de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
    Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
    Springer CJ; Poon GK; Sharma SK; Bagshawe KD
    Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations.
    Sharma SK; Bagshawe KD
    Adv Drug Deliv Rev; 2017 Sep; 118():2-7. PubMed ID: 28916498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein.
    Michael NP; Chester KA; Melton RG; Robson L; Nicholas W; Boden JA; Pedley RB; Begent RH; Sherwood RF; Minton NP
    Immunotechnology; 1996 Feb; 2(1):47-57. PubMed ID: 9373327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.